Esperion Therapeutics Inc
ESPR1.070USD
-0.030-2.73%
收盤 06/20, 16:00（美東）報價延遲15分鐘
210.43M總市值
虧損本益比TTM
關於 Esperion Therapeutics Inc 公司
Esperion Therapeutics, Inc. 是一家制藥公司。該公司專注於開發和商業化口服、每日一次、非他汀類藥物，用於治療低密度脂蛋白膽固醇 (LDL-C) 升高的患者。該公司的產品包括 NEXLETOL、NEXLIZET、NILEMDO 和 NUSTENDI。該公司的 NEXLETOL 和 NEXLIZET（貝培多酸和依折麥布）片劑是口服、每日一次、非他汀類藥物，用於治療患有雜合子家族性高膽固醇血癥 (HeFH) 或動脈粥樣硬化性心血管疾病 (ASCVD) 的成人原發性高脂血症。其 NEXLETOL 是一種 ATP 檸檬酸裂解酶 (ACL) 抑制劑，可通過減少膽固醇生物合成和上調 LDL 受體來降低 LDL-C。其 NUSTENDI 含有貝培多酸和依折麥布，通過互補作用機制抑制肝臟膽固醇合成和腸道吸收，從而降低升高的 LDL-C。其在研產品包括下一代 ACLYi。
公司簡介
公司代碼ESPR
公司名稱Esperion Therapeutics Inc
上市日期Jun 24, 2013
成立日期2008
CEOMr. Sheldon L. Koenig
員工數量304
證券類型Ordinary Share
年結日Jun 24
公司地址3891 Ranchero Drive, Suite 150
城市ANN ARBOR
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編48108
電話17348873903
網址https://www.esperion.com/
公司代碼ESPR
上市日期Jun 24, 2013
成立日期2008
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Sheldon L. Koenig
Mr. Sheldon L. Koenig
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
278.23K
-9.87%
Mr. Benjamin (Ben) Halladay
Mr. Benjamin (Ben) Halladay
Chief Financial Officer
Chief Financial Officer
83.51K
-7.97%
Mr. Stephen C. Rocamboli, J.D.
Mr. Stephen C. Rocamboli, J.D.
Independent Director
Independent Director
69.26K
+91.01%
Ms. Tracy M. Woody
Ms. Tracy M. Woody
Independent Director
Independent Director
33.57K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Independent Director
Independent Director
5.28K
--
Mr. Seth H. Z. Fischer
Mr. Seth H. Z. Fischer
Independent Director
Independent Director
--
--
Ms. Alina Venezia
Ms. Alina Venezia
IR Contact Officer
IR Contact Officer
--
--
Mr. J. Martin (Marty) Carroll
Mr. J. Martin (Marty) Carroll
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Benjamin O. Looker, Esq.
Mr. Benjamin O. Looker, Esq.
General Counsel
General Counsel
--
--
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Sheldon L. Koenig
Mr. Sheldon L. Koenig
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
278.23K
-9.87%
Mr. Benjamin (Ben) Halladay
Mr. Benjamin (Ben) Halladay
Chief Financial Officer
Chief Financial Officer
83.51K
-7.97%
Mr. Stephen C. Rocamboli, J.D.
Mr. Stephen C. Rocamboli, J.D.
Independent Director
Independent Director
69.26K
+91.01%
Ms. Tracy M. Woody
Ms. Tracy M. Woody
Independent Director
Independent Director
33.57K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Independent Director
Independent Director
5.28K
--
Mr. Seth H. Z. Fischer
Mr. Seth H. Z. Fischer
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
6.73%
The Vanguard Group, Inc.
5.80%
Wasatch Global Investors Inc
5.52%
Bellevue Asset Management AG
4.89%
Two Seas Capital LP
3.50%
Other
73.57%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
6.73%
The Vanguard Group, Inc.
5.80%
Wasatch Global Investors Inc
5.52%
Bellevue Asset Management AG
4.89%
Two Seas Capital LP
3.50%
Other
73.57%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
21.60%
Investment Advisor
19.65%
Hedge Fund
11.20%
Research Firm
6.05%
Bank and Trust
0.67%
Individual Investor
0.55%
Pension Fund
0.14%
Insurance Company
0.02%
Other
40.10%
機構持股
更新時間: 2月24日 週一
更新時間: 2月24日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
392
118.99M
60.06%
-48.18M
2024Q4
416
132.03M
67.01%
-41.92M
2024Q3
411
131.82M
67.24%
-43.99M
2024Q2
396
139.50M
73.71%
-8.75M
2024Q1
381
127.67M
67.51%
+27.09M
2023Q4
370
73.40M
64.38%
-30.67M
2023Q3
392
79.14M
69.19%
-24.19M
2023Q2
397
76.08M
79.96%
-27.32M
2023Q1
402
81.51M
91.10%
-9.43M
2022Q4
408
75.17M
98.39%
-2.65M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
13.09M
6.61%
-88.25K
-0.67%
Dec 31, 2024
The Vanguard Group, Inc.
11.72M
5.92%
-1.33M
-10.18%
Dec 31, 2024
Wasatch Global Investors Inc
24.48M
12.37%
+1.14M
+4.87%
Dec 31, 2024
Bellevue Asset Management AG
9.69M
4.9%
-250.00K
-2.51%
Mar 04, 2025
Two Seas Capital LP
6.23M
3.15%
-353.41K
-5.37%
Dec 31, 2024
Morgan Stanley & Co. LLC
5.06M
2.56%
+2.82M
+126.34%
Dec 31, 2024
Two Sigma Investments, LP
7.16M
3.62%
-68.60K
-0.95%
Dec 31, 2024
State Street Global Advisors (US)
4.50M
2.28%
+649.92K
+16.86%
Dec 31, 2024
Geode Capital Management, L.L.C.
4.34M
2.19%
+8.63K
+0.20%
Dec 31, 2024
Meditor Capital Management Limited
3.79M
1.92%
--
--
Sep 30, 2024
查看更多
持股ETF
更新時間: 6月6日 週五
更新時間: 6月6日 週五
機構名稱
佔比
Virtus LifeSci Biotech Products ETF
0.58%
SPDR S&P Pharmaceuticals ETF
0.4%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.33%
Principal U.S. Small-Cap ETF
0.06%
iShares Micro-Cap ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Global X Russell 2000 ETF
0.01%
查看更多
Virtus LifeSci Biotech Products ETF
佔比0.58%
SPDR S&P Pharmaceuticals ETF
佔比0.4%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比0.33%
Principal U.S. Small-Cap ETF
佔比0.06%
iShares Micro-Cap ETF
佔比0.04%
Invesco Nasdaq Biotechnology ETF
佔比0.02%
ProShares Ultra Nasdaq Biotechnology
佔比0.02%
iShares Russell 2000 ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
